Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06782477
PHASE1

A Study of STAR-0310 in Healthy Adult Participants

Sponsor: Astria Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

This is a randomized, double-blind, placebo-controlled, single ascending dose trial evaluating the safety, tolerability, PK, and immunogenicity of STAR-0310 in healthy adult participants. There are 4 planned cohorts and potentially up to 1 additional cohort which may comprise of healthy adult participants of Japanese descent.

Official title: A First-in-Human, Phase 1a, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, Single Ascending Dose Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of STAR-0310 in Healthy Adult Participants

Key Details

Gender

All

Age Range

18 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2025-01-07

Completion Date

2026-01

Last Updated

2025-11-04

Healthy Volunteers

Yes

Interventions

DRUG

STAR-0310

STAR-0310 will be administered as a subcutaneous bolus injection.

DRUG

Placebo

Placebo will be administered as a subcutaneous bolus injection.

Locations (1)

Austin Clinical Research Unit - Early Clinical Development

Austin, Texas, United States